Medical Design Online -- San Antonio based BiO2 Medical, Inc. has created a medical device that the company’s executives believe could save hundreds of thousands of lives per year. The company recently closed on a $7.5M Series B round, which includes about $6.5M of new capital that will be used to seek a CE Mark (Europe’s equivalent to FDA Approval) for its lead product, the Angel™ Vena Cava Filter Catheter. The device aims to prevent the occurrence of a pulmonary embolism (PE) in critically ill patients.
